Trial Profile
Expanded Access for CC-10004
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Behcet's syndrome
- Focus Expanded access; Therapeutic Use
- Sponsors Amgen
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2018 New trial record